Stockreport

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerabi...

Organovo Holdings, Inc.  (ONVO) 
NASDAQ:AMEX Investor Relations: organovo.com/about/contact/investor-relations
PDF SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment appro [Read more]